A Case of Paranoid Schizophrenia and Severe Antipsychotic-induced Parkinson's Disorder Treated with a Combination of Olanzapine and Lurasidone
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Ballon J, Stroup T
. Polypharmacy for schizophrenia. Curr Opin Psychiatry. 2013; 26(2):208-13.
PMC: 4026924.
DOI: 10.1097/YCO.0b013e32835d9efb.
View
2.
Mura G, Petretto D, Bhat K, Carta M
. Schizophrenia: from epidemiology to rehabilitation. Clin Pract Epidemiol Ment Health. 2012; 8:52-66.
PMC: 3434422.
DOI: 10.2174/1745017901208010052.
View
3.
Miyake N, Miyamoto S, Jarskog L
. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?. Clin Schizophr Relat Psychoses. 2012; 6(3):122-33.
DOI: 10.3371/CSRP.6.3.4.
View
4.
Carpenter Jr W, Davis J
. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012; 17(12):1168-73.
DOI: 10.1038/mp.2012.121.
View
5.
Nasrallah H, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J
. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013; 47(5):670-7.
DOI: 10.1016/j.jpsychires.2013.01.020.
View